These results indicate that we may have a clear metric to determine particularly aggressive cancers that have wide-spread mutations due to aberrant AID expression by measuring drop-off at ABC sites in patients diagnosed with ALL. The gene discussed is AICDA; the disease is acute lymphoblastic leukemia.